Last reviewed · How we verify
GRT6005
GRT6005 is a small molecule drug that targets the serotonin receptor.
GRT6005 is a small molecule drug that targets the serotonin receptor. Used for Treatment of chemotherapy-induced nausea and vomiting.
At a glance
| Generic name | GRT6005 |
|---|---|
| Also known as | Morphine |
| Sponsor | Tris Pharma, Inc. |
| Drug class | serotonin receptor antagonist |
| Target | 5-HT3 receptor |
| Modality | Small molecule |
| Therapeutic area | Gastrointestinal |
| Phase | Phase 2 |
Mechanism of action
GRT6005 works by selectively binding to the serotonin receptor, which leads to a decrease in serotonin levels in the body. This decrease in serotonin levels can help to reduce symptoms of certain conditions. The exact mechanism of action is not fully understood.
Approved indications
- Treatment of chemotherapy-induced nausea and vomiting
Common side effects
- Nausea
- Vomiting
- Headache
Key clinical trials
- Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain (PHASE2)
- CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer (PHASE3)
- CORAL XT - Open-label Extension Trial of the CORAL Trial (PHASE3)
- Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain. (PHASE2)
- A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users (PHASE1)
- Assessment of GRT6005 in Painful Osteoarthritis of the Knee (PHASE2)
- Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy (PHASE2)
- Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GRT6005 CI brief — competitive landscape report
- GRT6005 updates RSS · CI watch RSS
- Tris Pharma, Inc. portfolio CI